Cynapsus Therapeutics Announces DTC Approval

Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company") (TSX
VENTURE:CTH)(OTCQX:CYNAF) today announced that the common shares of the Company
(CUSIP 23257Y701) have been made eligible for book-entry delivery and depository
services of The Depository Trust Company (the "DTC") to facilitate electronic
settlement of transfers of its common shares in the United States.


"The ability to have Cynapsus shares electronically transferred between
brokerages in the United States is significantly more convenient and reduces the
costs incurred in trading shares," said Anthony Giovinazzo, President & CEO of
Cynapsus. "With our shares now traded electronically, existing investors benefit
from greater liquidity and execution speeds, while we've also opened the door to
new investors that may have been previously restricted from our stock."


About Cynapsus Therapeutics

Cynapsus is a specialty pharmaceutical company developing a convenient and easy
to use sublingual (oral) thin film strip for the acute rescue of "OFF" motor
symptoms of Parkinson's disease. Cynapsus' drug candidate, APL-130277, is an
easy-to-administer, fast-acting reformulation of apomorphine, which is the only
approved drug (in the United States, Europe, Japan and other countries) to
rescue patients from "OFF" episodes. Cynapsus is focused on maximizing the value
of APL-130277 by completing pivotal studies in advance of a New Drug Application
("NDA") expected to be submitted in 2016.


Over one million people in the U.S. and an estimated 4 to 6 million people
globally suffer from Parkinson's disease. Parkinson's disease is a chronic and
progressive neurodegenerative disease that impacts motor activity, and its
prevalence is increasing with the aging of the population. Based on a recent
study and the results of the Company's Global 500 Neurologists Survey, it is
estimated that between 25 percent and 50 percent of patients experience "OFF"
episodes in which they have impaired movement or speaking capabilities. Current
medications only control the disease's symptoms, and most drugs become less
effective over time as the disease progresses.


More information about Cynapsus (TSX VENTURE:CTH)(OTCQX:CYNAF) is available at
www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval
(SEDAR) at www.sedar.com.


Forward Looking Statements

This announcement contains "forward-looking statements" within the meaning of
applicable securities laws. Generally, these forward-looking statements can be
identified by the use of forward-looking terminology such as "plans", "expects"
or "does not expect", "is expected", "budget", "scheduled", "estimates",
"forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or
variations of such words and phrases or state that certain actions, events or
results "may", "could", "would", "might" or "will be taken", "occur" or "be
achieved". Forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results, level of
activity, performance or achievements of Cynapsus to be materially different
from those expressed or implied by such forward-looking statements, including
but not limited to those risks and uncertainties relating to Cynapsus' business
disclosed under the heading "Risk Factors" in its Annual Information Form filed
on August 30, 2013 and its other filings with the various Canadian securities
regulators which are available online at www.sedar.com. Although Cynapsus has
attempted to identify important factors that could cause actual results to
differ materially from those contained in forward-looking statements, there may
be other factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not place undue
reliance on forward-looking statements. Cynapsus does not undertake to update
any forward-looking statements, except in accordance with applicable securities
laws.


Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved
the contents of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Cynapsus Therapeutics Inc.
Anthony Giovinazzo
President and CEO
[phone] x225
[e-mail]


Cynapsus Therapeutics Inc.
Andrew Williams
COO & CFO
[phone] x253
[e-mail]